Literature DB >> 20954246

Clinical and hematologic findings in Noonan syndrome patients with PTPN11 gene mutations.

Murat Derbent1, Yekta Öncel, Kürşad Tokel, Birgül Varan, Ayşegül Haberal, A Canan Yazici, Eric Legius, Namik Özbek.   

Abstract

Reports on Noonan syndrome (NS) have documented multiple types of coagulation defects and bleeding diathesis, and a wide range of clinical presentations. Early studies suggested that a large proportion of NS patients have coagulation defects, whereas more recent reports indicate low rates of coagulopathy. The aim of this study was to evaluate phenotypic characteristics, PTPN11 gene mutations, and hematological and coagulation parameters in 30 clinically diagnosed cases of NS. One of the NS patients had a history of easy bruising; however, his hematological and coagulation tests were normal. None of the other patients had clinical coagulation problems. In the NS group, values for platelet count, activity of factors XI, XII, and protein C were significantly lower than the corresponding means for the control group. However, the results of coagulation tests in the NS group were diagnostically inconclusive and only one patient had clinical signs of coagulopathy. Interestingly, two NS patients had low protein C activity. One of these children had an A1517C mutation and transient myelodysplasia. The other patient had a C1528G mutation in exon 13 that has not been reported previously. Neither of these individuals experienced a thrombotic event or any complication during approximately 3 years of follow-up. For all patients clinically diagnosed with NS, a thorough history of coagulation issues should be taken and first-line coagulation testing should be done to evaluate for bleeding diathesis. However, if these assessments reveal nothing abnormal, complications related to coagulation are unlikely and extensive testing is unnecessary.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20954246     DOI: 10.1002/ajmg.a.33713

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  8 in total

1.  Modifier variant of METTL13 suppresses human GAB1-associated profound deafness.

Authors:  Rizwan Yousaf; Zubair M Ahmed; Arnaud Pj Giese; Robert J Morell; Ayala Lagziel; Alain Dabdoub; Edward R Wilcox; Sheikh Riazuddin; Thomas B Friedman; Saima Riazuddin
Journal:  J Clin Invest       Date:  2018-03-12       Impact factor: 14.808

2.  Phenotypic spectrum of 80 Greek patients referred as Noonan syndrome and PTPN11 mutation analysis: the value of initial clinical assessment.

Authors:  Anna Papadopoulou; Michalis Issakidis; Evangelia Gole; Konstantina Kosma; Helen Fryssira; Andreas Fretzayas; Polyxeni Nicolaidou; Sophia Kitsiou-Tzeli
Journal:  Eur J Pediatr       Date:  2011-05-18       Impact factor: 3.183

3.  New Genetic Insights into Congenital Heart Disease.

Authors:  Stephanie M Ware; John Lynn Jefferies
Journal:  J Clin Exp Cardiolog       Date:  2012-06-15

4.  Severe congenital thrombocytopaenia--first clinical manifestation of Noonan syndrome.

Authors:  Paula Nunes; Sara Aguilar; Sara Noéme Prado; Maria João Palaré; Anabela Ferrão; Anabela Morais
Journal:  BMJ Case Rep       Date:  2012-03-20

Review 5.  The genetics of common variation affecting platelet development, function and pharmaceutical targeting.

Authors:  A D Johnson
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

6.  Evaluation of bleeding disorders in patients with Noonan syndrome: a systematic review.

Authors:  Diane J Nugent; Alicia A Romano; Shreya Sabharwal; David L Cooper
Journal:  J Blood Med       Date:  2018-10-23

7.  Pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: the multifaceted consequences of PTPN11 mutations.

Authors:  Giulio Calcagni; Maria Cristina Digilio; Bruno Marino; Marco Tartaglia
Journal:  Orphanet J Rare Dis       Date:  2019-07-05       Impact factor: 4.123

8.  Prolonged thrombocytopenia in a neonate with Noonan syndrome: a case report.

Authors:  Meng Li; Jinghui Zhang; Nianzheng Sun
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.